Literature DB >> 21994514

Effects of long-term combination treatment with valproate and atypical antipsychotics on bone mineral density and bone metabolism in premenopausal patients with bipolar disorder: a preliminary study.

Jaewon Yang1, Sook-Haeng Joe, Moon-Soo Lee, Young-Hoon Ko, In-Kwa Jung, Seung-Hyun Kim.   

Abstract

OBJECTIVE: We investigated bone mineral density (BMD) and bone metabolism in female bipolar patients who were undergoing long-term treatment with valproate combined with a low-dose atypical antipsychotic.
METHODS: Nineteen premenopausal women with bipolar disorder who were treated with valproate combined with atypical antipsycho-tics for at least 2 years were evaluated. The BMD was measured at lumbar spine and femur sites using dual-energy X-ray absorptiometry (DE-XA). The biochemical markers of bone turnover and circulating levels of gonadal hormones were assessed. Subjects with abnormal DEXA scans were compared to those with normal scans.
RESULTS: Nine (47%) of nineteen subjects showed osteopenia or osteoporosis. The T-score for subjects with abnormal DEXA scans was -1.988. Decreased BMD was more prominent in the proximal femur than in the lumbar spine. Subjects with abnormal DEXA scans had high phosphorus and low testosterone levels relative to subjects with normal scans (p=0.008 and p=0.028, respectively). There was a significant negative correlation between phosphorus, osteocalcin, and femur neck BMD (p<0.05). However, multivariate analysis did not show a significant association between femur and lumbar BMD and biochemical markers of bone turnover.
CONCLUSION: Long-term treatment with valproate combined with low-dose atypical antipsychotics may adversely affect BMD in premenopausal women with bipolar disorder. A prospective, controlled-study with a larger population is warranted, and assessment of BMD and bone metabolism should be taken into consideration in long-term therapy with valproate and atypical antipsychotics.

Entities:  

Keywords:  Bipolar disorder; Bone density; Bone metabolism; Females; Valproate

Year:  2011        PMID: 21994514      PMCID: PMC3182392          DOI: 10.4306/pi.2011.8.3.256

Source DB:  PubMed          Journal:  Psychiatry Investig        ISSN: 1738-3684            Impact factor:   2.505


  21 in total

1.  The role of stress-induced cortisol in the relationship between depression and decreased bone mineral density.

Authors:  Patricia M Furlan; Tom Ten Have; Mark Cary; Babette Zemel; Felix Wehrli; Ira R Katz; David R Gettes; Dwight L Evans
Journal:  Biol Psychiatry       Date:  2005-04-15       Impact factor: 13.382

2.  Low bone density with the use of valproate.

Authors:  Ayesha Waheed; Paul A Kettl
Journal:  Gen Hosp Psychiatry       Date:  2005 Sep-Oct       Impact factor: 3.238

3.  Osteoporosis demonstrated by dual energy x-ray absorptiometry in chronic schizophrenic patients.

Authors:  G Abraham; R H Friedman; C Verghese
Journal:  Biol Psychiatry       Date:  1996-09-01       Impact factor: 13.382

4.  Decreased bone density in hyperprolactinemic women.

Authors:  A Klibanski; R M Neer; I Z Beitins; E C Ridgway; N T Zervas; J W McArthur
Journal:  N Engl J Med       Date:  1980-12-25       Impact factor: 91.245

5.  Bone density and antiepileptic drugs: a case-controlled study.

Authors:  L J Stephen; A R McLellan; J H Harrison; D Shapiro; M H Dominiczak; G J Sills; M J Brodie
Journal:  Seizure       Date:  1999-09       Impact factor: 3.184

6.  Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia?

Authors:  Veronica O'Keane; Anna Maria Meaney
Journal:  J Clin Psychopharmacol       Date:  2005-02       Impact factor: 3.153

7.  The effect of valproate on bone mineral density in adult epileptic patients.

Authors:  Ayhan Boluk; Mehmet Guzelipek; Haluk Savli; Ismail Temel; Handan Işin Ozişik; Akif Kaygusuz
Journal:  Pharmacol Res       Date:  2004-07       Impact factor: 7.658

8.  Bone mineral density in women with depression.

Authors:  D Michelson; C Stratakis; L Hill; J Reynolds; E Galliven; G Chrousos; P Gold
Journal:  N Engl J Med       Date:  1996-10-17       Impact factor: 91.245

9.  Effect of long-term valproate monotherapy on bone mineral density in adults with epilepsy.

Authors:  Nikos Triantafyllou; Irini Lambrinoudaki; Elena Armeni; Eleftheria-Maria Evangelopoulos; Fotini Boufidou; Aris Antoniou; Georgios Tsivgoulis
Journal:  J Neurol Sci       Date:  2010-01-06       Impact factor: 3.181

10.  Bone mineral metabolism changes in epileptic children receiving valproic acid.

Authors:  N Oner; M Kaya; S Karasalihoğlu; H Karaca; C Celtik; F Tütüncüler
Journal:  J Paediatr Child Health       Date:  2004-08       Impact factor: 1.954

View more
  4 in total

1.  Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder.

Authors:  Christoph U Correll; Johan Detraux; Jan De Lepeleire; Marc De Hert
Journal:  World Psychiatry       Date:  2015-06       Impact factor: 49.548

2.  Expression of prolactin receptors in the duodenum, kidneys and skeletal system during physiological and sulpiride-induced hyperprolactinaemia.

Authors:  Danijela Radojkovic; Milica Pesic; Milan Radojkovic; Dragan Dimic; Marija Vukelic Nikolic; Tatjana Jevtovic Stoimenov; Sasa Radenkovic; Milena Velojic Golubovic; Tatjana Radjenovic Petkovic; Slobodan Antic
Journal:  Endocrine       Date:  2018-08-24       Impact factor: 3.633

3.  Association between bipolar spectrum disorder and bone health: a meta-analysis and systematic review protocol.

Authors:  Vinoomika Chandrasekaran; Sharon L Brennan-Olsen; Amanda L Stuart; Julie A Pasco; Michael Berk; Jason M Hodge; Lana J Williams
Journal:  BMJ Open       Date:  2017-02-28       Impact factor: 2.692

4.  Association Between Bipolar Disorder and Low Bone Mass: A Cross-Sectional Study With Newly Diagnosed, Drug-Naïve Patients.

Authors:  Sujuan Li; Yan Qui; Ziwei Teng; Jindong Chen; Dongyu Kang; Hui Tang; Hui Xiang; Chujun Wu; Yuxi Tan; Lu Wang; Yanyi Yang; Bolun Wang; Haishan Wu
Journal:  Front Psychiatry       Date:  2020-06-10       Impact factor: 4.157

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.